Yichao Zhang

Yichao Zhang

Auto-generated profile, based on publicly available information

Yichao Zhang

Department of Neurosurgery, Huashan Hospital, Fudan University , Shanghai

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
BLBen Lin
Ben Lin
MWMeng Wang
Meng Wang
RGRenyuan Gao
Renyuan Gao
ZYZhao Ye
Zhao Ye
YYYifei Yu
Yifei Yu
YZYichao Zhang
Yichao Zhang
Dysbiosis of gut microbiota is associated not only with intestinal disorders but also with numerous extraintestinal diseases. Growth hormone-secreting pituitary adenoma (GHPA) is an insidious disease with persistent hypersecretion of GH and IGF-1, causing increased morbidity and mortality.

10 January 2023 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
BLBen Lin
Ben Lin
ZYZhen Ye
Zhen Ye
ZYZhao Ye
Zhao Ye
MWMeng Wang
Meng Wang
ZCZhan Cao
Zhan Cao
YZYichao Zhang
Yichao Zhang
In recent decades, various roles of the gut microbiota in physiological and pathological conditions have been uncovered. Among the many interacting pathways between the host and gut flora, the gut–brain axis has drawn increasing attention and is generally considered a promising way to understand and treat brain tumors, one of the most lethal neoplasms. In this narrative review, we aimed to unveil and dissect the sophisticated mechanisms by which the gut‐brain axis exerts its influence on brain tumors. Furthermore, we summarized the latest research regarding the gastrointestinal microbial landscape and the effect of gut–brain axis malfunction on different brain tumors. Finally, we outlined the ongoing developing approaches of microbial manipulation and their corresponding research related to neuro‐malignancies. Collectively, we recapitulated the advances in gut microbial alterations along with their potential interactive mechanisms in brain tumors and encouraged increased efforts in this area.

2 January 2024 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
ZCZhengyuan Chen
Zhengyuan Chen
XSXuefei Shou
Xuefei Shou
LJLijin Ji
Lijin Ji
HCHaixia Cheng
Haixia Cheng
MSMing Shen
Ming Shen
YWYongfei Wang
Yongfei Wang
Objective To review experience regarding the treatment of prolactinomas by endoscopic endonasal surgery focusing on the association between presurgical dopamine agonist (DA) treatment and perioperative outcomes, surgical morbidities, endocrine outcomes, and pathological characteristics. Methods A single-center series of 290 cases was analyzed retrospectively and clinical data were collected. Intratumoral collagen content was assessed by Masson trichrome staining. Results Tenacious tumor consistency (27.8% vs 9.8%, P < .001) was more common in DA-pretreated patients compared with patients who underwent initial surgery. Moreover, DA-pretreated macroadenomas presented more intraoperative blood loss (200 [100-400] mL vs 175 [100-300] mL; P = .014), longer surgical duration (177 ± 95 minutes vs 154 ± 57 minutes; P = .043), and more surgical morbidities (19.4% vs 8.9%; P = .034). Additionally, DA-pretreated macroadenomas presented a higher collagen volume fraction than that of the initial surgery group (23.6 ± 2.2% vs 13.2 ± 2.1%; P = .001). Correlation analysis revealed a close correlation between collagen volume fraction and the cumulative dose of bromocriptine (BRC) in macroadenomas (r = 0.438, P < .001). Regarding endocrine outcomes, DA-pretreated microadenomas showed a lower proportion of initial remission compared with patients who underwent initial surgery (86.7% vs 100%, P = .047). Conclusion This study described increased surgical difficulty and inferior endocrine outcomes associated with tumor fibrosis secondary to presurgical BRC treatment in prolactinomas. Neurosurgeons should note that presurgical BRC treatment may render subsequent surgery more challenging.

1 December 2024 in Radiology
Verified
Journal Article
Closed access
YWYue Wu
Yue Wu
YWYanfei Wu
Yanfei Wu
BYBoyuan Yao
Boyuan Yao
SRShuhua Ren
Shuhua Ren
SWShiman Wu
Shiman Wu
ZYZhenwei Yao
Zhenwei Yao
In a prospective study involving 43 participants with Cushing disease, the incorporation of gallium 68 (68Ga) pentixafor PET/MRI demonstrated promising sensitivity, which was higher than contrast-enhanced MRI alone in localizing adrenocorticotropic hormone–secreting pituitary tumors.

17 April 2022 in Nutrition & Dietetics
Verified
Journal Article
Closed access
YWYing‐Ke Wu
Ying‐Ke Wu
MLMan Li
Man Li
YZYi‐Chao Zhang
Yi‐Chao Zhang
RGRui‐Zhen Gao
Rui‐Zhen Gao
YSYang Su
Yang Su
Weixing WangWeixing Wang
Weixing Wang

12 June 2024 in mBio
Verified
Journal Article
Open access
JSJingqian Su
Jingqian Su
WCWenzhi Chen
Wenzhi Chen
FZFen Zhou
Fen Zhou
RLRui Li
Rui Li
ZTZhiyong Tong
Zhiyong Tong
LCLong Chen
Long Chen
Despite its high mortality, specific and effective drugs for sepsis are lacking. Decoy receptor 3 (DcR3) is a potential biomarker for the progression of inflammatory diseases. The recombinant human DcR3-Fc chimera protein (DcR3.Fc) suppresses inflammatory responses in mice with sepsis, which is critical for improving survival. The Fc region can exert detrimental effects on the patient, and endogenous peptides are highly conducive to clinical application. However, the mechanisms underlying the effects of DcR3 on sepsis are unknown. Herein, we aimed to demonstrate that DcR3 may be beneficial in treating sepsis and investigated its mechanism of action. Recombinant DcR3 was obtained in vitro . Postoperative DcR3 treatment was performed in mouse models of lipopolysaccharide- and cecal ligation and puncture (CLP)-induced sepsis, and their underlying molecular mechanisms were explored. DcR3 inhibited sustained excessive inflammation in vitro , increased the survival rate, reduced the proinflammatory cytokine levels, changed the circulating immune cell composition, regulated the gut microbiota, and induced short-chain fatty acid synthesis in vivo . Thus, DcR3 protects against CLP-induced sepsis by inhibiting the inflammatory response and apoptosis. Our study provides valuable insights into the molecular mechanisms associated with the protective effects of DcR3 against sepsis, paving the way for future clinical studies. IMPORTANCE: Sepsis affects millions of hospitalized patients worldwide each year, but there are no sepsis-specific drugs, which makes sepsis therapies urgently needed. Suppression of excessive inflammatory responses is important for improving the survival of patients with sepsis. Our results demonstrate that DcR3 ameliorates sepsis in mice by attenuating systematic inflammation and modulating gut microbiota, and unveil the molecular mechanism underlying its anti-inflammatory effect.